Beam Therapeutics stock hits 52-week high at 36.89 USD
Beam Therapeutics Inc. (BEAM) stock has surged to a new 52-week high of $36.89, currently trading at $37.02, reflecting a 90.88% increase over the past year. This growth is attributed to investor confidence in its genetic medicine approaches and recent positive developments, including FDA clearance for BEAM-304 and promising clinical data from BEAM-302 and BEACON trials. Analysts like H.C. Wainwright have reiterated a "Buy" rating with an $80.00 price target, highlighting the company's progress and strategic initiatives.
Understanding the Setup: (BEAM) and Scalable Risk
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM) through AI models, identifying a near-term neutral sentiment amidst mid and long-term strength. It presents specific trading strategies for different risk profiles, including long, breakout, and short setups, and highlights an exceptional 48.4:1 risk-reward short setup. The analysis incorporates multi-timeframe signal analysis to provide entry, target, and stop-loss levels.
FMR LLC Reduces Stake in Beam Therapeutics Inc.
FMR LLC significantly reduced its stake in Beam Therapeutics Inc. by 86.38%, selling over 10 million shares at $35.24 each. Despite this reduction, Beam Therapeutics still represents 1.65% of FMR LLC's holdings, indicating continued belief in the biotechnology company. Beam Therapeutics, known for its precision genetic medicines, is considered modestly overvalued with a GF Score of 70/100, signaling potential challenges in future performance.
Beam Therapeutics (NASDAQ: BEAM) CMO sells 373 shares for tax withholding
Amy Simon, Chief Medical Officer at Beam Therapeutics Inc. (NASDAQ: BEAM), sold 373 shares of common stock for $34.73 each. This non-discretionary transaction was undertaken to cover tax withholding obligations associated with the vesting of restricted stock units granted under the company's 2019 Equity Incentive Plan. Following this sale, Simon directly holds 102,363 shares of Beam Therapeutics common stock, and the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Following FDA Clearance, Is Beam Therapeutics (BEAM) Already Priced In?
Beam Therapeutics (BEAM) has seen its investigational new drug application for BEAM-304 cleared by the FDA, allowing a Phase 1/2 trial to proceed for phenylketonuria patients. Despite a strong share price performance over the past year, the article explores whether the stock, currently trading around $33.48, is undervalued given a popular narrative pegging its fair value at $150 per share based on its "Gene Editing 2.0" platform, or if its future growth is already priced in, especially considering its high P/S ratio compared to industry averages and peers.
BEAM - Beam Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial overview for Beam Therapeutics Inc. (BEAM). It includes detailed financial metrics such as market capitalization, income, sales, EPS, P/E ratios, employee count, and stock performance data, offering a snapshot of the company's financial health and market position.
Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan
Beam Therapeutics (BEAM) CEO John M. Evans exercised options for 50,000 shares and subsequently sold the same number of shares through open-market transactions at weighted average prices in the mid-$30s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following these sales, Evans still maintains significant holdings, directly owning over 1.0 million shares and indirectly holding 103,000 shares through a trust.
BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise
An insider at Beam Therapeutics Inc. (NASDAQ: BEAM) filed a Form 144 to sell 25,000 common shares through a stock option exercise on June 29, 2026. This regulatory filing indicates an intent to sell, and similar prior transactions by John M. Evans were detailed, including sales in March and April 2026. The transaction will involve a cash payment to the issuer.
Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock
A 10% shareholder of Beam Therapeutics (BEAM.US) recently sold a significant amount of common stock, totaling US$10.04 million. This transaction indicates a notable insider sale that could be of interest to investors tracking company performance.
FMR LLC sells $10.04 million in Beam Therapeutics shares
FMR LLC, a major shareholder, recently sold Beam Therapeutics Inc. (NASDAQ:BEAM) shares worth approximately $10.04 million in late June, with sales occurring at weighted average prices between $35.12 and $35.26. The stock is trading near its 52-week high after a 107% gain over the last year, though InvestingPro analysis suggests it may be overvalued. Concurrently, Beam Therapeutics announced FDA clearance for its BEAM-304 drug and presented positive clinical data for BEAM-302 and ristoglogene autogetemcel, leading H.C. Wainwright to reiterate a Buy rating with an $80 price target.
FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale
FMR LLC, a significant owner of Beam Therapeutics Inc., reported trimming its stake by selling a total of 284,860 common shares through indirect open-market sales. These sales, executed via F-Prime Capital Partners Healthcare Fund V LP on June 25th and 26th, 2026, were valued at over $10 million, with weighted average prices around $35 per share. Despite these sales, FMR LLC and its affiliated entities retain substantial indirect holdings in Beam Therapeutics.
How FDA Clearance of BEAM-304’s Platform Trial for PKU May Impact Beam Therapeutics (BEAM) Investors
Beam Therapeutics announced FDA clearance for its BEAM-304 IND application for PKU, featuring a platform-style trial designed to test multiple base editors within a single clinical framework. While this strengthens Beam's in vivo liver editing story and provides a near-term clinical catalyst, investors should consider the ongoing risks related to clinical safety, regulatory outcomes, and funding needs as the company remains unprofitable. The success of this platform approach and other similar trials, like BEAM-302, will be crucial in validating Beam's technology and justifying its current valuation, especially if regulators adopt a cautious stance on umbrella genome editing trials.
Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM)
This article provides financial actuals and estimates for Beam Therapeutics Inc. (NASDAQ:BEAM), offering insights into its stock performance, analyst forecasts, and company financials. It details BEAM's current stock price, market capitalization, historical highs and lows, and upcoming earnings report date. The company's revenue and net income for recent quarters, along with EBITDA and employee count, are also presented.
Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM)
This article provides financial actuals and estimates for Beam Therapeutics, Inc. (BEAM) traded on the Mexican Stock Exchange (BMV). It details current stock price, historical performance, analyst forecasts, volatility, market capitalization, and upcoming earnings reports. Key financial figures like past earnings and revenue are also discussed.
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026
Beam Therapeutics (BEAM) saw its short interest increase by 31.94% to 28.31 million shares as of June 15, 2026, representing 28.60% of its public float. The short interest ratio or "days to cover" stands at 14.2, indicating strong pessimism among investors. This article provides a detailed historical breakdown of BEAM's short interest, dollar volume sold short, and price on report dates.
Price to sales forward of Beam Therapeutics Inc. – NASDAQ:BEAM
The article focuses on the "Price to sales forward" metric for Beam Therapeutics Inc. (NASDAQ: BEAM). It provides a high-level view of this financial data point, indicating it is one of the many financial details available for the company on the TradingView platform. The content is primarily a data label within a financial charting and analysis service.
The Technical Signals Behind (BEAM) That Institutions Follow
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM) through the lens of technical signals, highlighting strong sentiment across all horizons and an exceptional risk-reward setup targeting a 16.8% gain. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with a multi-timeframe signal analysis. The report provides specific entry, target, and stop-loss levels derived from AI models for institutional trading strategies.
Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304
Beam Therapeutics (BEAM) is under investor focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing therapy. The stock is currently trading at US$33.20, while a narrative fair value suggests it could be 77.9% undervalued at $150. This valuation hinges on the long-term success of Beam's precision "molecular pencil" base editing platform, which is considered a safer and more precise alternative to traditional gene editing methods.
Beam Therapeutics stock hits 52-week high at 36.66 USD By Investing.com
Beam Therapeutics (BEAM) stock recently hit a 52-week high of $36.66, reflecting a 104.31% increase over the past year. Despite being considered overvalued by InvestingPro, investor confidence is high due to recent FDA clearance for BEAM-304, progress in BEAM-302 trials, and positive analyst ratings. The company is actively advancing its pipeline with clinical data presentations and ongoing development for various treatments.
Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading
Beam Therapeutics Inc. president Giuseppe Ciaramella exercised stock options on June 17, 2026, to acquire 35,505 shares of common stock. These transactions were "M" coded, indicating exercises of derivative securities rather than open-market purchases and reflect long-term equity compensation with vesting schedules beginning in 2018. The options had strike prices of $1.03 and $0.67 per share, and no shares were sold in this filing.
Beam Therapeutics stock hits 52-week high at 36.66 USD
Beam Therapeutics (BEAM) stock has reached a 52-week high of $36.66, currently trading slightly below this peak at $36.50. The biotech company has seen a 104.31% appreciation over the past year, reflecting strong investor confidence despite being considered overvalued by InvestingPro analysis. Recent developments, including FDA clearance for BEAM-304 and positive clinical trial data presentations, contribute to its strong market performance.
Beam Therapeutics stock hits 52-week high at 36.66 USD
Beam Therapeutics (BEAM) stock has hit a 52-week high of $36.66, reflecting strong investor confidence and positive market sentiment. The company has seen a 104.31% appreciation over the past year and continues to advance its clinical pipeline with recent FDA clearance for BEAM-304 and promising BEAM-302 trial data. Despite an "overvalued" assessment by InvestingPro, analysts like H.C. Wainwright maintain a Buy rating due to the company's progress in clinical trials.
Clinical: Beam Advances Base Editing For PKU
Beam Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for BEAM-304, an in vivo base-editing therapy designed for phenylketonuria (PKU). This program is notable for its platform-based strategy, aiming to develop multiple mutation-specific editors within a single clinical framework. The approach seeks to streamline the development of genome-editing therapies for genetically diverse liver disorders.
Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial
Beam Therapeutics' stock rose 16.1% following FDA clearance of its Investigational New Drug (IND) application for BEAM-304, a platform-based gene-editing therapy for phenylketonuria (PKU). This clearance, particularly its platform design allowing multiple mutation-specific base editors under a single trial, could be a significant validation for Beam's broader base-editing approach in liver diseases. The company's investment narrative continues to depend on the scalability of its base editing technology across various diseases and the progress of its BEAM-302 program.
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Shares of Beam Therapeutics rose 5% after the FDA cleared the investigational new drug (IND) application for BEAM-304, its gene-editing therapy for phenylketonuria (PKU). BEAM-304 is a liver-targeted therapy designed to correct mutations in the PAH gene to lower toxic phenylalanine levels, with Beam planning a phase I/II clinical study. The company aims to restore normal dietary capabilities for PKU patients and expand its genetic disease franchise.
Beam Therapeutics gets FDA clearance for BEAM-304
Beam Therapeutics (NASDAQ:BEAM) has received FDA clearance for its Investigational New Drug (IND) application for BEAM-304, a base-editing therapy for phenylketonuria (PKU). This clearance allows the company to initiate a Phase 1/2 clinical trial to evaluate the safety and efficacy of BEAM-304 in human patients. The therapy aims to correct PAH gene mutations and normalize plasma phenylalanine levels using an in vivo base-editing approach delivered via lipid nanoparticles.
Beam Therapeutics gets FDA clearance for PKU gene therapy trial
Beam Therapeutics (NASDAQ:BEAM) has received FDA clearance for its investigational new drug application for BEAM-304, a gene therapy for phenylketonuria (PKU). The company's stock rose following the announcement, reflecting a 91% return over the past year. BEAM-304 uses base editing technology to correct mutations causing PKU, and preclinical data showed promising results in normalizing phenylalanine levels.
Beam gets FDA clearance for BEAM-304 PKU gene-editing trial
Beam Therapeutics announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for BEAM-304, a base-editing candidate for phenylketonuria (PKU). This clearance allows Beam to initiate a Phase 1/2 clinical trial for BEAM-304, which aims to correct PAH gene mutations and normalize phenylalanine levels in PKU patients. The program uses a platform approach to develop multiple mutation-specific base editors within a single clinical program.
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
Beam Therapeutics announced that the U.S. FDA has cleared its investigational new drug (IND) application for BEAM-304, a base-editing therapy for phenylketonuria (PKU). This innovative approach aims to correct mutations in the PAH gene to restore enzyme activity and reduce toxic phenylalanine levels, leveraging emerging FDA guidance for accelerated development of genome editing therapies. The company plans to initiate a Phase 1/2 trial to establish clinical proof of concept for base editing in PKU.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
Beam Therapeutics (BEAM) stock has surged 21% in the past three months, vastly outperforming the industry's 4.5% decline. This growth is attributed to positive clinical developments, rapid regulatory progress across its pipeline, and the company's strong financial position. Key drivers include encouraging early data from the BEAM-302 study for alpha-1 antitrypsin deficiency and several other upcoming pipeline catalysts for genetic diseases.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
Beam Therapeutics (BEAM) stock has surged 21% in the last three months due to positive clinical data from its BEAM-302 candidate for alpha-1 antitrypsin deficiency (AATD), which showed promising results in a phase I/II study. The company also anticipates multiple pipeline catalysts, including BLA submissions and new drug applications, further bolstered by a strong financial position with a cash runway expected to last until mid-2029. This has reassured investors about its ability to fund ongoing clinical development.
BEAM Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Beam Therapeutics Inc (BEAM), focusing on its revenue breakdown, profitability margins, and a comparison with competitors like RCUS and DYN. BEAM maintains a 100% gross margin but exhibits negative operating and net margins, and a negative Return on Equity. The company has a market capitalization of $3.19B, positioning it as a leader in its sector.
Amova Asset Management Americas Inc. Cuts Stock Position in Beam Therapeutics Inc. $BEAM
Amova Asset Management Americas Inc. has reduced its stake in Beam Therapeutics Inc. ($BEAM) by 8.7% in the fourth quarter, selling 421,438 shares, though it still holds 4.35% of the company. Company insiders also sold shares, totaling approximately $1.9 million over the past three months, primarily for tax withholding on equity awards. Despite these sales, Beam Therapeutics reported strong quarterly revenue growth and earnings per share that exceeded analyst expectations, leading to a consensus "Moderate Buy" rating from analysts with an average price target of $46.83.
Beam Therapeutics (BEAM) Is Up 5.2% After Positive BEAM-302 Data Hints At Accelerated FDA Pathway
Beam Therapeutics (BEAM) saw a 5.2% stock increase following positive clinical trial data for its gene-editing candidate BEAM-302. The data suggests potential for an accelerated FDA review pathway for treating alpha-1 antitrypsin deficiency, strengthening Beam's genetic medicine pipeline. While this offers a near-term catalyst and extends the company's financial runway into mid-2029, investors are cautioned about the reliance on early-stage data and the need for successful pivotal trials to validate Beam's base editing platform.
Geode Capital Management LLC Sells 39,035 Shares of Beam Therapeutics Inc. $BEAM
Geode Capital Management LLC reduced its stake in Beam Therapeutics Inc. by 1.6% in the fourth quarter, selling 39,035 shares but still holding 2.35 million shares valued at $65.2 million. Despite the sale, institutional investors own 99.68% of the company's stock. Beam Therapeutics reported a smaller-than-expected quarterly loss and significantly higher revenue, leading analysts to maintain a "Moderate Buy" rating with an average target price of $46.83.
Beam Therapeutics (Nasdaq: BEAM) shareholders approve directors, auditor and pay
Beam Therapeutics (Nasdaq: BEAM) shareholders approved the election of three Class III directors, John Evans, John Maraganore, Ph.D., and Christi Shaw, at their 2026 annual meeting. Shareholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and gave advisory approval to the compensation of the company's named executive officers. All proposals received strong shareholder support.
Beam Therapeutics (BEAM) Valuation After Positive BEAM 302 Data And Accelerated FDA Pathway Potential
Beam Therapeutics (BEAM) is regaining investor attention after new clinical data for its BEAM-302 program showed sustained protective protein levels, potentially supporting an accelerated FDA review. Despite recent share price volatility, the company's "molecular pencil" base editing technology offers precision genetic medicine. While a narrative fair value suggests the stock is significantly undervalued at $150 compared to its current price of $29.40, risks remain regarding future data outcomes and regulatory decisions.
Beam Therapeutics (BEAM) awards stock options to director Chirfi
Beam Therapeutics director Guindo Chirfi was granted 19,676 stock options as equity compensation, with an exercise price of $29.55 per share and an expiration date of June 3, 2036. The options will vest either on the first anniversary of the grant date or immediately before the next annual stockholders' meeting, provided Chirfi remains on the board. This transaction is categorized as routine director compensation, not an open-market purchase or sale.
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts
Beam Therapeutics Inc. (NASDAQ:BEAM) has received a "Moderate Buy" consensus rating from 14 research firms, with an average 12-month price target of $46.83. The company recently exceeded earnings expectations, reporting EPS of -$0.91 against estimates of -$1.03 and revenue of $31.74 million, significantly higher than the $10.98 million consensus. Despite a recent 7% drop in share price, institutional investors hold 99.68% of the company, though insiders have recently sold shares.
Beam Therapeutics (BEAM) grants 19,676 stock options to director
Beam Therapeutics (BEAM) director John Maraganore was granted 19,676 stock options with an exercise price of $29.55 per share, expiring on June 3, 2036. These options vest fully on the earlier of one year from the grant date or just before the next annual shareholders' meeting, provided he remains on the board. This transaction was reported via a Form 4 SEC filing and constitutes compensation-related equity rather than open-market trading.
Beam Therapeutics (BEAM) director receives 19,676-share option grant
Beam Therapeutics director Christi Shaw was granted stock options to purchase 19,676 shares of Common Stock at an exercise price of $29.55 per share. These options vest upon the earlier of one year from the grant date or immediately before the next annual stockholders' meeting, contingent on her continued board service, and are set to expire on June 3, 2036. Following this grant, Shaw directly holds 19,676 derivative securities.
Beam Therapeutics (BEAM) awards director Graham Cooper 19,676 options
Beam Therapeutics Inc. director Graham K. Cooper was granted 19,676 stock options with an exercise price of $29.55 per share, expiring on June 3, 2036. The options vest fully on the earlier of the first anniversary of the grant date or immediately before the next annual stockholder meeting, contingent on his continued service to the board. Following this grant, Cooper holds 19,676 derivative securities directly, and no open-market transactions were reported.
Beam Therapeutics Stock Hits Day Low of $28.80 Amid Price Pressure
Beam Therapeutics (NASDAQ: BEAM) stock experienced a significant decline, dropping 7.0% to an intraday low of $28.80, despite a 324.87% rise in quarterly net sales. The company's performance contrasts with a slight increase in the S&P 500. Over the longer term, the stock has seen substantial drops, falling 14.9% over three years and 63.63% over five years, though institutional holdings remain high at 100%.
Technical Reactions to BEAM Trends in Macro Strategies
This article provides a technical analysis of Beam Therapeutics Inc. (NASDAQ: BEAM) by the Quantitative Research Desk at Stock Traders Daily. It highlights neutral near and mid-term readings, a potential long-term positive bias, and an exceptional risk-reward short setup. The analysis also includes institutional trading strategies and multi-timeframe signal analysis for BEAM.
A Look At Beam Therapeutics (BEAM) Valuation After Updated BEAM 302 Trial Data And Accelerated Approval Plans
Beam Therapeutics (BEAM) has gained attention following updated Phase 1/2 BEAM-302 trial data for alpha-1 antitrypsin deficiency, showing positive safety and durability signals. Despite recent stock momentum, the company's valuation is a subject of debate, with a narrative estimating fair value at $150 against a current sales multiple suggesting overvaluation. Investors are encouraged to assess the inherent risks and rewards before making investment decisions.
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
The article announces that an anti-aging cell therapy has achieved a significant GMP (Good Manufacturing Practice) milestone, indicating progress in its development. This achievement comes amidst a growing number of clinical advancements in the field. The piece highlights the ongoing momentum in anti-aging research and development.
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD
Beam Therapeutics (BEAM) stock surged 17.6% after the company announced plans to seek accelerated approval for its drug BEAM-302, designed to treat alpha-1 antitrypsin deficiency (AATD). The drug's base-editing approach addresses both liver and lung manifestations of AATD, with updated Phase 1/2 data showing detailed safety, durability, and human neutrophil elastase findings. This development strengthens Beam Therapeutics' investment narrative, potentially establishing BEAM-302 as a significant value driver alongside its other therapeutic programs.
The "Molecular Pencil": Why Beam's Technology is Built to Win
The article highlights Beam Therapeutics' base editing platform as a "molecular pencil," offering a safer and more precise alternative to traditional CRISPR "molecular scissors" for genetic medicine. It details the success of BEAM-302 for AATD and the potential of the ESCAPE platform to revolutionize gene therapy by eliminating pre-transplant chemotherapy. The author also provides a valuation estimate for Beam of $65 per share, based on an rNPV model of its lead assets, with significant upside potential not yet priced in.
Why Beam Therapeutics (BEAM) Is Up 13.1% After Pursuing Accelerated Approval For BEAM-302
Beam Therapeutics (BEAM) saw a 13.1% stock increase after announcing plans to seek accelerated FDA approval for BEAM-302, a gene-editing therapy for alpha-1 antitrypsin deficiency. The company aims to restore physiologic alpha-1 antitrypsin responses and plans to expand its pivotal trial. This move highlights Beam's strategy to translate its base-editing platform into revenue-generating therapies, supported by significant capital and existing pipeline programs.
Beam Therapeutics Accelerated Approval Bid Puts BEAM-302 At Center Stage
Beam Therapeutics announced encouraging Phase 1/2 clinical data for BEAM-302 in alpha-1 antitrypsin deficiency and plans to pursue an accelerated approval pathway. This strategy positions BEAM-302 as a critical program, concentrating more of Beam's value on its success alongside sickle cell disease. Investors will closely watch upcoming detailed data, pivotal cohort design, and how the company manages its financial runway and competitive landscape against other gene-editing firms.
